What changed
$TMO — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $11.0B | EPS $5.44 vs $5.24 🟢 | Margin 21.8%
💡 Consensus models low-to-mid single-digit revenue growth and gradual margin normalization, while actual results show 6% revenue growth and resilient margins. The variant view is that new product launches and the PPI Business System will sustain above-consensus earnings, driving upward revisions and a re-rating from 20x forward P/E toward 22-23x.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 8/10
📊 Valuation: fair
🔮 Catalyst: Q2 2026 earnings report and potential guidance raise at upcoming healthcare conferences
💰 Entry: $461.69, stop $430, target $540
⚖️ Buy TMO: Post-earnings estimate revisions should drive ~15% upside in 3 months, with a 2.5:1 risk/reward ratio backed by durable fundamentals and a catalyst-rich period ahead.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/TMO0617